EGFR and exanthem: Skin rash is frequently associated with the administration of epidermal growth factor receptor (EGFR) inhibitors, including tyrosine kinase inhibitors, such as gefitinib and erlotinib, and anti-EGFR monoclonal antibodies, such as cetuximab and panitumumab [2].